Carteolol
Chemical compound
From Wikipedia, the free encyclopedia
Carteolol is a non-selective beta blocker used to treat glaucoma. It is administered in the form of eye drops.[citation needed]
| |
| Clinical data | |
|---|---|
| Trade names | Ocupress |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a601078 |
| License data | |
| Routes of administration | Eye drops |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 85% |
| Metabolism | Liver, active with 8-hydrocarteolol |
| Elimination half-life | 6–8 hours |
| Excretion | Kidney (50–70%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H24N2O3 |
| Molar mass | 292.379 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (verify) | |
Carteolol was patented in 1972 and approved for medical use in 1980.[1]
Pharmacology
Pharmacodynamics
Carteolol is a beta blocker, or an antagonist of the β-adrenergic receptors.[2] It is selective for the β1-adrenergic receptor and has intrinsic sympathomimetic activity.[2] Carteolol has also been found to act as a serotonin 5-HT1A and 5-HT1B receptor antagonist in addition to being a beta blocker.[3]
Pharmacokinetics
Carteolol is classified as a beta blocker with low lipophilicity and hence lower potential for crossing the blood–brain barrier.[2] This in turn may result in fewer effects in the central nervous system as well as a lower risk of neuropsychiatric side effects.[2]
Chemistry
The experimental log P of carteolol is 1.1 and its predicted log P ranges from 0.99 to 2.39.[4][5][6][7] It is a hydrophilic or low-lipophilicity beta blocker.[7][2]
Society and culture
Brand names
Brand names of carteolol include Arteolol, Arteoptic, Calte, Cartéabak, Carteol, Cartéol, Cartrol, Elebloc, Endak, Glauteolol, Mikelan, Ocupress, Poenglaucol, Singlauc, and Teoptic.